BPN14770

BPN14770, assigned the proposed nonproprietary name zatolmilast, is a small-molecule allosteric inhibitor of phosphodiesterase-4D (PDE4D), one of the enzyme subtypes that break down the intracellular second messenger cyclic adenosine monophosphate (cAMP) ^[1][2]. Rather than blocking the enzyme's catalytic pocket the way older phosphodiesterase-4 inhibitors do, it binds a regulatory region known as UCR2 that folds over the active site, and it preferentially targets the activated, dimeric form of the enzyme ^[1]. This binding mode exploits a single amino-acid difference between rodent and human PDE4D, which turns out to matter a great deal for how the compound is studied ^[2][4].

The molecule was designed and synthesized at Tetra Discovery Partners, later Tetra Therapeutics, whose PDE4D program was subsequently acquired by Shionogi, and it was optimized through iterative rounds of X-ray crystallography and metabolite analysis ^[1]. A central goal of the medicinal-chemistry work was to keep the memory-enhancing benefits of phosphodiesterase-4 inhibition while cutting the nausea, vomiting, and vascular side effects that stalled development of earlier, nonselective inhibitors of the enzyme family ^[1][2]. Because the relevant allosteric site differs by one amino acid between species, researchers created humanized PDE4D mice, in which the mouse sequence was edited to match the human version, so the drug's engagement with its target could be tested in a living animal ^[2][4].

Preclinical studies reported broad cognitive and neuroprotective activity. In humanized mice BPN14770 improved performance on memory tasks and countered the amnesia produced by scopolamine while raising markers of neuronal plasticity such as brain-derived neurotrophic factor ^[2]. It protected memory, dendritic structure, and synaptic proteins against injury from amyloid-beta, the peptide implicated in Alzheimer's disease ^[3], and it reversed scopolamine-induced deficits through a cAMP-linked signaling cascade ^[4]. In a mouse model of Fragile X syndrome, a genetic cause of intellectual disability, chronic treatment improved several behavioral abnormalities ^[5]. On the strength of such findings the compound advanced into midstage human phase 2 clinical trials, chiefly for Fragile X syndrome, and it has also been investigated for Alzheimer's disease ^[1].

BPN14770 remains an investigational agent and has not received marketing approval; it is met in the scientific literature and clinical-trial registries rather than as an approved medicine ^[1]. Because Fragile X syndrome is a rare condition, the drug's clinical development has been pursued along the lines used for rare-disease therapies. As an experimental molecule it exists as an oral clinical-trial formulation and a research compound rather than a commercial product.

BPN14770 is an investigational drug, not a supplement, but it has a better human track record than most compounds at this stage. In its Phase 2 Fragile X trial it was very well tolerated with few adverse events, and the PDE4D-selective design meaningfully reduced the GI side effects (nausea, headache, digestive upset) that dog non-selective PDE4 inhibitors. That said, there is no long-term consumer safety data, and it is not approved or available as a product. Originally from Tetra Therapeutics and now developed by Shionogi under the name zatolmilast, it has been advancing through later-stage trials rather than sitting on a shelf.

BPN14770, now assigned the name zatolmilast, was developed by the American company Tetra Discovery Partners under the direction of Mark Gurney as an allosteric inhibitor of the phosphodiesterase-4D enzyme. Unlike classic PDE4 inhibitors that block the conserved catalytic site, it binds a regulatory domain and only partially inhibits the enzyme, a design intended to raise brain cyclic AMP for cognitive benefit while avoiding the nausea and vomiting that limited earlier compounds.

Because the relevant allosteric pocket differs by a single amino acid between rodents and humans, the developers engineered genetically humanized PDE4D mice to study the drug meaningfully. It advanced into phase 2 clinical trials, including a study in Fragile X syndrome led by Elizabeth Berry-Kravis that reported cognitive improvement, and rights were later licensed to Shionogi; it is not approved for medical use.

BPN14770 is viewed as one of the more scientifically interesting entrants in cognitive and neurodevelopmental drug research, notable for a clever allosteric, subtype-selective strategy that aims to capture the pro-cognitive upside of PDE4 inhibition while sidestepping its historical tolerability problems. Its phase 2a signal in adults with Fragile X syndrome, a condition with few options, generated genuine optimism, reinforced by later analyses linking blood levels of the drug to an objective brain electrophysiology marker. It also attracted attention for Alzheimer's disease research through its ability to boost cAMP, CREB, and BDNF signaling. It remains an investigational compound, and its promise is appropriately framed as encouraging but not yet established.